Replies to post #766948 on NorthWest Biotherapeutics Inc (NWBO)

[beartrap12]

SkyLimit, you said:

In my view, IFR eligibility may soon become irrelevant with the pending MAA decision—but it’s still awesome to see that IFR access is now available while we await MHRA’s forthcoming decision!

But isn't it possible/likely that MHRA added Murcidencel/DCVax-L to the IFR program because they want to allow it to be used for patients with other cancers after DCVax-L MAA is completed/approved?? And couldn't results of these IFR cases lead to tumor -agnostic designation sooner rather than later?

PS: I enjoy reading your responses to Fudsters!

[GoodGuyBill]

Regarding

In my view, IFR eligibility may soon become irrelevant with the pending MAA decision—but it’s still awesome to see that IFR access is now available while we await MHRA’s forthcoming decision!

I agree:

What is likely happening here is that NHS has looked at all of DCVax-L's data and concluded that they need to get this treatment to its citizenry NOW. So, the NHS is using IFR funding to jump-start DCVax-L accessibility. It's as if NHS said to NICE, " DCVax-L is a godsend. We need to make this available now. I know you have to go through your process before our citizenry can have full access to DCVax-L but we are going to place DCVax-L on the HCD list to make this available NOW while you work through your process." Were you aware that NHS added significant additional funding to cancer treatment in 2024? Now you know why.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176178126